Classification of visual field abnormalities in the Ocular Hypertension Treatment Study

John L Keltner, Chris A. Johnson, Kimberly E. Cello, Mary A. Edwards, Shannan E. Bandermann, Michael A. Kass, Mae O. Gordon

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Objectives: (1) To develop a classification system for visual field (VF) abnormalities, (2) to determine interreader and test-retest agreement, and (3) to determine the frequency of various VF defects in the Ocular Hypertension Treatment Study. Methods: Follow-up VFs are performed every 6 months and are monitored for abnormality, indicated by a glaucoma hemifield test result or a corrected pattern SD outside the normal limits. As of January 1, 2002, 1636 patients had 2509 abnormal VFs. Three readers independently classified each hemifield using a classification system developed at the VF reading center. A subset (50%) of the abnormal VFs was reread to evaluate test-retest reader agreement. A mean deviation was calculated separately for the hemifields as an index to the severity of VF loss. Main Outcome Measures: A 97% interreader hemifield agreement. Results: The average hemifield classification agreement (between any 2 of 3 readers) for 5018 hemifields was 97% and 88% for the 1266 abnormal VFs that were reread (agreement between the first and second classifications). Glaucomatous patterns of loss (partial arcuate, paracentral, and nasal step defects) composed the majority of VF defects. Conclusion: The Ocular Hypertension Treatment Study classification system has high reproducibility and provides a possible nomenclature for characterizing VF defects.

Original languageEnglish (US)
Pages (from-to)643-650
Number of pages8
JournalArchives of Ophthalmology
Volume121
Issue number5
DOIs
StatePublished - May 1 2003

Fingerprint

Ocular Hypertension
Visual Fields
Therapeutics
Nose
Terminology
Glaucoma
Reading
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Keltner, J. L., Johnson, C. A., Cello, K. E., Edwards, M. A., Bandermann, S. E., Kass, M. A., & Gordon, M. O. (2003). Classification of visual field abnormalities in the Ocular Hypertension Treatment Study. Archives of Ophthalmology, 121(5), 643-650. https://doi.org/10.1001/archopht.121.5.643

Classification of visual field abnormalities in the Ocular Hypertension Treatment Study. / Keltner, John L; Johnson, Chris A.; Cello, Kimberly E.; Edwards, Mary A.; Bandermann, Shannan E.; Kass, Michael A.; Gordon, Mae O.

In: Archives of Ophthalmology, Vol. 121, No. 5, 01.05.2003, p. 643-650.

Research output: Contribution to journalArticle

Keltner, JL, Johnson, CA, Cello, KE, Edwards, MA, Bandermann, SE, Kass, MA & Gordon, MO 2003, 'Classification of visual field abnormalities in the Ocular Hypertension Treatment Study', Archives of Ophthalmology, vol. 121, no. 5, pp. 643-650. https://doi.org/10.1001/archopht.121.5.643
Keltner, John L ; Johnson, Chris A. ; Cello, Kimberly E. ; Edwards, Mary A. ; Bandermann, Shannan E. ; Kass, Michael A. ; Gordon, Mae O. / Classification of visual field abnormalities in the Ocular Hypertension Treatment Study. In: Archives of Ophthalmology. 2003 ; Vol. 121, No. 5. pp. 643-650.
@article{07bf103f20194602986c681756a2759d,
title = "Classification of visual field abnormalities in the Ocular Hypertension Treatment Study",
abstract = "Objectives: (1) To develop a classification system for visual field (VF) abnormalities, (2) to determine interreader and test-retest agreement, and (3) to determine the frequency of various VF defects in the Ocular Hypertension Treatment Study. Methods: Follow-up VFs are performed every 6 months and are monitored for abnormality, indicated by a glaucoma hemifield test result or a corrected pattern SD outside the normal limits. As of January 1, 2002, 1636 patients had 2509 abnormal VFs. Three readers independently classified each hemifield using a classification system developed at the VF reading center. A subset (50{\%}) of the abnormal VFs was reread to evaluate test-retest reader agreement. A mean deviation was calculated separately for the hemifields as an index to the severity of VF loss. Main Outcome Measures: A 97{\%} interreader hemifield agreement. Results: The average hemifield classification agreement (between any 2 of 3 readers) for 5018 hemifields was 97{\%} and 88{\%} for the 1266 abnormal VFs that were reread (agreement between the first and second classifications). Glaucomatous patterns of loss (partial arcuate, paracentral, and nasal step defects) composed the majority of VF defects. Conclusion: The Ocular Hypertension Treatment Study classification system has high reproducibility and provides a possible nomenclature for characterizing VF defects.",
author = "Keltner, {John L} and Johnson, {Chris A.} and Cello, {Kimberly E.} and Edwards, {Mary A.} and Bandermann, {Shannan E.} and Kass, {Michael A.} and Gordon, {Mae O.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1001/archopht.121.5.643",
language = "English (US)",
volume = "121",
pages = "643--650",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Classification of visual field abnormalities in the Ocular Hypertension Treatment Study

AU - Keltner, John L

AU - Johnson, Chris A.

AU - Cello, Kimberly E.

AU - Edwards, Mary A.

AU - Bandermann, Shannan E.

AU - Kass, Michael A.

AU - Gordon, Mae O.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Objectives: (1) To develop a classification system for visual field (VF) abnormalities, (2) to determine interreader and test-retest agreement, and (3) to determine the frequency of various VF defects in the Ocular Hypertension Treatment Study. Methods: Follow-up VFs are performed every 6 months and are monitored for abnormality, indicated by a glaucoma hemifield test result or a corrected pattern SD outside the normal limits. As of January 1, 2002, 1636 patients had 2509 abnormal VFs. Three readers independently classified each hemifield using a classification system developed at the VF reading center. A subset (50%) of the abnormal VFs was reread to evaluate test-retest reader agreement. A mean deviation was calculated separately for the hemifields as an index to the severity of VF loss. Main Outcome Measures: A 97% interreader hemifield agreement. Results: The average hemifield classification agreement (between any 2 of 3 readers) for 5018 hemifields was 97% and 88% for the 1266 abnormal VFs that were reread (agreement between the first and second classifications). Glaucomatous patterns of loss (partial arcuate, paracentral, and nasal step defects) composed the majority of VF defects. Conclusion: The Ocular Hypertension Treatment Study classification system has high reproducibility and provides a possible nomenclature for characterizing VF defects.

AB - Objectives: (1) To develop a classification system for visual field (VF) abnormalities, (2) to determine interreader and test-retest agreement, and (3) to determine the frequency of various VF defects in the Ocular Hypertension Treatment Study. Methods: Follow-up VFs are performed every 6 months and are monitored for abnormality, indicated by a glaucoma hemifield test result or a corrected pattern SD outside the normal limits. As of January 1, 2002, 1636 patients had 2509 abnormal VFs. Three readers independently classified each hemifield using a classification system developed at the VF reading center. A subset (50%) of the abnormal VFs was reread to evaluate test-retest reader agreement. A mean deviation was calculated separately for the hemifields as an index to the severity of VF loss. Main Outcome Measures: A 97% interreader hemifield agreement. Results: The average hemifield classification agreement (between any 2 of 3 readers) for 5018 hemifields was 97% and 88% for the 1266 abnormal VFs that were reread (agreement between the first and second classifications). Glaucomatous patterns of loss (partial arcuate, paracentral, and nasal step defects) composed the majority of VF defects. Conclusion: The Ocular Hypertension Treatment Study classification system has high reproducibility and provides a possible nomenclature for characterizing VF defects.

UR - http://www.scopus.com/inward/record.url?scp=0037653688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037653688&partnerID=8YFLogxK

U2 - 10.1001/archopht.121.5.643

DO - 10.1001/archopht.121.5.643

M3 - Article

C2 - 12742841

AN - SCOPUS:0037653688

VL - 121

SP - 643

EP - 650

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 5

ER -